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Abstract Cancer is a complex organ whose behavior is not
only influenced by genetic and epigenetic changes in cancer
cells but also by stromal cells, local extracellular matrix and
specific tissue architecture. Intercellular communications within
the cancer microenvironment are critical to coordinate the as-
sembly of multiple cell types for an amalgamated form and
function of a cancer. Exosomes are small membrane vesicles
with an endosome origin that are released by cells into the
extracellular environment. They carry a cargo of proteins, lip-
ids, and nucleic acids and transfer their cargo to recipient cells
and altering the recipient cells’ biochemical composition, sig-
naling pathways, and gene regulation. Exosomes can thus serve
as extracellular messengers mediating cell-cell communication.
Both cancer cells and stromal cells release exosomes not only
into the cancer microenvironment but also into the circulation.
In this review, we summarize the research done so far on
cancer-derived exosomes and assess their roles as extracellular
messengers facilitating cancer progression and metastasis.
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Introduction
Exosomes
Exosomes are small extracellular membrane vesicles with a
mean size of 40–100 nm that are released by cells either
spontaneously or by induction. They were first described as
exfoliated membrane vesicles that contain 5′-nucleotidase
activity and released from neoplastic cell lines [1]. Soon
after, other groups reported the secretion of small vesicles
that were originated from endosomes in cultured reticulo-
cytes and were present inside multivesicular bodies
(MVBs). These small vesicles were shown to have a func-
tion in clearing the transferrin receptor and other obsolete
proteins during the maturation of reticulocytes to erythro-
cytes [2–6].Exosomes represent a subset of secreted mem-
brane vesicles and are generally identified by having a
buoyant density of 1.10 to 1.21 g/ml in sucrose, a size range
from 30 nm to 200 nm, a cup shaped appearance by electron
microscopy and sedimentation by ultracentrifugation at the
speed of at least 100,000 × g with prior centrifugation at a
lower speed to remove larger membrane vesicles [7]. Other
types of secreted membrane vesicles include microvesicles
(MVs) also called microparticles (MPs) or ectosomes which
are generated from most cell types by plasma membrane
shedding/budding/apoptotic blebbing with a wide size range
from 50 nm to 1 μm. MVs are sometimes also used as a
general term to describe all secreted membrane vesicles
including exosomes. As there is yet any definite nomencla-
ture for the different types of vesicles, in this review we will
use MVs to indicate membrane vesicles released by mem-
brane shedding/budding/apoptotic blebbing. The larger MVs
are generally isolated by centrifugation at a speed of 10,000 -
20,000 × g. MVs with sizes in the range of exosomes cannot
be easily distinguished from exosomes through the
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differential centrifugation method. Further analysis of bio-
chemical markers such as endosomal markers Alix, CD9
and CD63 are thus required to confirm exosome identity.
Thus, the membrane vesicle populations in vitro and in vivo
are often mixtures of exosomes plus MVs. Exosome prep-
arations prepared through ultracentrifugation at 100,000 × g
commonly used in various published studies most likely
also contain other small MVs. Hence, stringent purification
methods and consensus characteristics for identifying exo-
somes need to be established [8, 9].
Exosomes come from the intraluminal vesicles (ILVs) of
MVBs that are formed through the inward budding of late
endosome membrane (Fig. 1). When MVBs fuse with plas-
ma membrane, exosomes are released as part of their cargo.
During the formation of exosomes, there are two membrane
inversion events. The first occurs at the plasma membrane
during endocytic internalization and the second occurs when
the endosome membrane bud inwardly, encapsulating some
of cell’s cytoplasm including RNA, protein, and even DNA.
As a result, molecules are retained in the same inside-outside
configuration (positive orientation) in ILVs, allowing exo-
somes to have the same orientation as the cell membrane
upon their release to the extracellular environment (summa-
rized in [10, 11]). (Note: There are many excellent reviews
on exosomes in the past few years. We apologize that we
could not cite all of them.)
Many cell types have been described to release exosomes
into the extracellular medium in vitro such as hematopoietic
cells (B cells, T cells, dendritic cells, mast cells, platelets),
intestinal epithelial cells, Schwann cells, neuronal cells,
adipocytes, fibroblasts, tumour cells, etc. They are also
found in vivo in several biological fluids such as urine,
plasma, epididymal fluid, amniotic liquid, malignant and
pleural effusions of ascites, bronchoalveolar lavage fluid,
synovial fluid and breast milk.
The composition of exosomes varies depending on the
cell type of origin. Over the years, various techniques such
as Western blotting, mass spectrometry, fluorescence-
activated cell sorting, and immunoelectron microscopy have
been used to analyze the content of exosomes. They contain
RNAs, lipids and 350–400 proteins [12]. Common exosome
proteins include annexins that regulate membrane cytoskele-
ton dynamics and membrane fusion events; Rab family of
GTPases which promote docking and membrane fusion
events; and ESCRT (endosomal sorting complex required
for transport) proteins [13–15]. Other proteins include tetra-
spanins (CD81, CD63, CD9) and heat shock proteins (HSP60,
HSP70, HSP90) which can facilitate peptide loading onto
major histocompatibility complex (MHC) I and II [16, 17].
Exosomes also express cell-specific markers such as MHC
class I and II, co-stimulatory proteins (CD80 and CD86) on
antigen presenting cell-derived exosomes, integrin CD41a
and Von Willebrand factor on platelet-derived exosomes,
and perforin and granzyme on cytotoxic T-lymphocyte-
derived exosomes [18–20]. A number of adhesion molecules
have also been reported in exosomes including CD146, CD9,
EGFRvIII, CD18, CD11a, CD11b, CD11c, CD166 and LFA-
3/CD58 [21, 22]. In addition, metabolic enzymes such as
peroxidases, pyruvate kinase, lipid kinases and enolase-1 are
also reported to be present in exosomes [12].
Fig. 1 A schematic diagram depicting the formation of exosome through ILV of MVB
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Similarly, the composition of MVs also varies depending
on the cell type of origin [23]. The membrane composition
of MVs is distinct from its parental cell plasma membrane
with significant structural remodelling. For example, in
MVs, phosphatidylserine is relocated to the outer membrane
leaflet while the topology of membrane proteins remains
intact [24–26]. This is a distinct feature of MVs that is
different from exosomes. In addition, MVs also in general
do not contain endosomal proteins.
The current general consensus seems to be that the major
differences between exosomes and other secreted membrane
vesicles are the mechanism of secretion and size. However,
due to the overlap in sizes of exosomes and small MVs
generated through membrane shedding/budding, some pre-
viously reported findings regarding exosomes or microve-
sicles may actually involve a mixture of exosomes and
MVs. In this review, we will use the term “exosomes” for
studies involving extracellular membrane vesicles isolated
through ultracentrifugation at 100,000 x g even though in
some cases, these preparations may contain heterogeneous
types of vesicles.
Exosomes can be internalized by recipient cells through
mechanisms such as endocytosis, phagocytosis, micropino-
cytosis or even direct membrane lipid fusion [27–30]. Up-
take of exosomes by recipient cells rely on a variety of
recipient cell surface receptors as well as exosome surface
proteins such as integrins, annexins, galectin, and ICAM1
[27, 31]. Not only proteins (both cytoplasmic and cell sur-
face transmembrane proteins) but also mRNA and miRNA
are transferred to the recipient cells by exosomes [32–34].
Exosomes can thus alter the recipient cell’s molecular pro-
file, signalling pathways and gene regulation and serve as
extracellular messengers that can transfer information from
the donor cell to the recipient cell.
Cancer Microenvironment
It is now well accepted that a cancer is a complex organ
whose behavior is not only influenced by genetic and epi-
genetic changes in the cancer cells but also by stromal cells,
local extracellular matrix (ECM) and specific tissue archi-
tecture [35]. Conceivably, the cancer microenvironment is
influenced by both the cancer cells as well as stromal cells.
Cancer cells maneuver the cancer microenvironment to one
that favors cancer progression and metastasis by influencing
stromal cells and the ECM. On the other hand, the stromal
cells carry the local tissue influences and architectural cues
which also influence cancer behavior. Hence, intercellular
communication is critical in the cancer microenvironment to
coordinate the assembly of multiple cell types for an amal-
gamated form and function of a cancer [36].
The massive cancer cell proliferation in cancer quickly
lead to a cancer microenvironment that is hypoxic, acidic,
and deprived of nutrients. Such hostile microenvironment
put on a powerful selection pressure which select cells that
are hypoxia-resistant, highly invasive, genetically unstable,
and with an altered metabolism re-programming to metabo-
lize glucose by aerobic glycolysis rather than by oxidative
phosphorylation (reviewed in [36–38]). Hypoxia activates
the hypoxia-inducible factor 1 (HIF1) which stimulate the
expression of vascular endothelial growth factor (VEGF)
and many other angiogenesis growth factors and chemo-
kines. Altered glycolytic metabolism lead to extracellular
acidity with a selection of tumor cells armed to avoid intra-
cellular accumulation of acids. Maintaining the intracellular
pH is crucial to normal cell function because many cellular
biochemical processes have a narrow pH optimum. To
counteract cytosolic acidification, tumor cells mobilize pro-
ton pumps to pump H+ into the extracellular environment,
thus generating an acidic microenvironment.
Cancer microenvironment is also rich in cytokines and
chemokines which attract large number of immune cells into
the cancer microenvironment. The cancer-localized immune
cells in turn release more cytokines and chemokines which
influence cancer cell survival and migration. In addition,
cancer extracellular environment is also rich in matrix met-
alloproteinases which help to promote angiogenesis, cancer
cell invasion and metastasis. High level of extracellular
adenosine level in cancer due to metabolic changes also
suppress immune function and help cancer to evade immune
surveillance (reviewed in [37].
Thus, cancer microenvironment is unique and it changes
according to the oncogene/tumor suppressor gene mutations
and host factors. Cells in cancer (parenchymal cancer cells
and stromal cells) communicate with and influence each
other by releasing soluble factors and ECM proteins. In
addition, cells also release lipid membrane enclosed vesicles
such as exosomes and other secreted membrane vesicles,
which play important roles as extracellular messengers not
only within the cancer and but also between the cancer and
the host environment.
Exosomes as Extracellular Messengers in the Cancer
Microenvironment
It is now believed that many types of cells can release
exosomes including cells in cancer, although the amount
released in vivo is not clear. Here we examine the possible
roles exosomes play in cancer microenvironment.
Exosomes Released by Cancer Cells
The intercellular exchange of proteins and nucleic acids
within the cancer microenvironment could be an effective
local communication route that plays important roles in
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promoting cancer progression and metastasis. Exosomes
released by cancer cells can not only transmit signals to
other cancer cells, but also to stromal cells within the cancer
microenvironment, thus impacting the cancer ECM archi-
tecture and generating cancer microenvironment.
Cancer-derived Exosomes Promote Cancer Growth
Glioblastoma-derived exosomes were reported to stimulate
glioma cell proliferation and promote cancer growth in a
self-promoting manner [34] (Although this paper described
the membrane vesicles (MVs) used as microvesicles, these
MVs are most likely exosomes judging from the isolation
method used). In another study, the anti-apoptotic protein
survivin was shown to be released into exosomes by cervi-
cal carcinoma cells. In particular, this survivin exosomal
release is significantly upregulated after proton irradiation-
induced stress, suggesting that exosomes may be involved
in cancer cell self protection under stress. Furthermore,
extracellular survivin was able to enhance proliferation,
survival and cancer cell invasion, indicating the significance
of exosome-mediated survivin release in cancer progres-
sion [39]. Significantly, ovarian carcinoma patients were
found to release exosomes into the ascites and blood circu-
lation and become systemic. Application of malignant
ascites-derived exosomes to cancer bearing mice resulted
in augmented cancer growth, indicating that cancer-derived
exosomes promote cancer progression [40]. In yet another
study, human breast and colorectal cancer cells were shown
to release exosomes containing signaling-competent EGFR
ligands [41]. By analyzing exosomes released from cultured
MDCK cells expressing individual EGFR ligand, exosomes
carrying amphiregulin (AREG) were found to most potently
enhance the invasiveness of breast cancer cells. Significant-
ly, AREG exosomes displayed 5-times more invasive po-
tential over equivalent amounts of recombinant AREG.
AREG exosomes are shown to be rapidly internalized by
recipient cells [41]. Furthermore, the authors revealed that
exosomes from colon cancer cells with a mutant KRAS
allele exhibited both higher AREG levels and greater inva-
sive potential than exosomes from isogenically matched,
nontransformed cells in which mutant KRAS was eliminat-
ed by homologous recombination. Hence, EGFR ligand can
signal via exosomes and this may contribute to cancer
progression and metastasis.
The cancer microenvironment is long believed to be
unique as a result of mutual influences between cancer cells
and stromal cells. A recent report indicated that the cancer
microenvironment also influences the components and func-
tions of cancer-derived exosomes [42]. In that report, it was
demonstrated that co-culture of leukocytes isolated from
breast cancer tissue led to uptake of fibronectin (FN) into
the cancer exosomes. The uptake of FN into exosomes is
cancer tissue derived and leukocyte specific, as leukocytes
isolated from the peripheral blood of naive mice failed to
induce FN uptake by cancer exosomes. They further identi-
fied the CD25(+)and Gr-1(+) subset of cancer-associated
leucocytes which are mainly responsible for promoting FN
uptake by cancer exosomes. In response to absorbing of FN
(+) exosomes, focal adhesion kinase/Src-dependent signal-
ing pathways are activated, and the production of proin-
flammatory cytokines and metalloproteinase 9 is enhanced,
causing enhanced cancer cell invasion in vitro and in vivo.
This work also highlighted the fact that exosomes released
from in vitro cultured cells may be functionally different
from exosomes in the in vivo tissue environment.
Cancer-derived Exosomes Stimulate Angiogenesis
Exosomes released by cancer cells have been shown to
promote angiogenesis. Exosomes produced by mouse B16
melanoma cells were shown to promote endothelial tubule
formation and stimulate production of endothelial spheroids.
In addition, B16 exosomes stimulated pro-angiogenic cyto-
kine production in endothelial cells (ECs) such as IL-1α,
FGF, GCS-F, TNFα, Leptin, TGFα, and VEGF while high
doses of exosomes suppressed pro-inflammatory cytokines
including TREM-1, I-TAC, IL-3, and IL-16 [43]. Exosomes
derived from glioblastoma also promoted angiogenesis and
mRNAs carried by glioblastoma exosomes can be translated
in the recipient ECs [34]. Colorectal cancer cell-derived
exosomes are shown to be enriched in cell cycle-related
mRNAs and promoted the proliferation of ECs [44]. In
another study, MVs produced by human cancer cells har-
boring activated EGFR (A431, A549, DLD-1) were shown
to be taken up by cultured ECs and elicit EGFR-dependent
responses in the recipient ECs including activation of
MAPK and Akt pathways, initiation of VEGF expression
and activation of key VEGF signalling receptor VEGF
receptor-2 [45]. The MVs used in this study were obtained
from the normal method of exosome isolation (ultracentri-
fugation at 100,000 × g with prior removal of large micro-
vesicles by low speed centrifugation) and it is conceivable
that these MVs contain exosomes [45]. In another study,
cancer-derived exosomes containing the tetraspanin Tspan8
(also called D6.1A) were shown to efficiently induce angio-
genesis in cancers by stimulating angiogenic factor tran-
scription such as VEGF and VEGFR [46]. Tspan8
exosomes bind to ECs through Tspan8-CD49d complex
and become internalized, leading to enhanced EC prolifera-
tion, migration, sprouting, and maturation of EC progenitors
[47]. Under hypoxia, cancer cells were found to secrete
many cytoplasmic and membrane proteins involved in pro-
moting angiogenesis and metastasis through the release of
exosomes that enhance the angiogenic and metastatic po-
tential and modulate its cancer microenvironment [48]. The
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transmembrane notch ligand delta like 4 (Dll4) has been
demonstrated to be incorporated into cancer cell exo-
somes [49]. These exosomes can transfer the Dll4 pro-
tein to ECs and incorporate it into their cell membrane.
This results in inhibition of Notch signaling and con-
fers a tip cell phenotype to the recipient ECs and an
increase in angiogenesis. Transfer of Dll4 was also
shown in vivo from cancer cells to host endothelium
through exosomes. All together, these results indicate
that cancer cell derived exosomes play an important
role in cancer growth and metastasis by facilitating
angiogenesis.
Cancer-derived Exosomes Modulate Stromal Cell Function
It has been shown that some cancer-derived exosomes could
trigger fibroblast differentiation into myofibroblasts and
elicit a significant upregulation of FGF2 expression in the
recipient cells [50]. These exosomes express TGF-β at their
surface in association with the transmembrane proteoglycan
betaglycan and can elicit SMAD-dependent signalling in the
recipient fibroblasts. Enrichment of myofibroblasts in solid
cancers represents an alteration of the stroma into one that
typically supports cancer growth, vascularization and
metastasis.
Cancer-derived Exosomes Modify the ECM
The exosomes isolated from malignant ascitic fluid of ovar-
ian carcinoma patients were shown to contain gelatinolytic
enzymes and the presence of these exosome-associated
enzymes in the cancer vicinity might augment cancer
invasion [51]. Cancer-derived exosomes also carry ex-
tracellular matrix remodelling enzymes such as MMP2,
MMP9 and urokinase plasminogen activator (uPA), leading to
increased cancer ECM degradation and cancer invasiveness
[52–54].
The L1 adhesion molecule (CD171) is overexpressed in
human ovarian and endometrial carcinomas and is associat-
ed with poor prognosis. Although expressed as a transmem-
brane molecule, L1 is released from carcinoma cells in
soluble form. Soluble L1 is present in serum and ascites of
ovarian carcinoma patients and is a potent inducer of cell
migration. It may also stimulate cell proliferation by acti-
vating extracellular signal-regulated kinase (ERK). Cancer-
derived exosomes are shown to be an important source of
soluble L1 [55]. Exosomes derived from ovarian carcinoma
cells contain transmembrane metalloprotease such as AD-
AM10 that cleaves the transmembrane L1 and facilitates the
release of the cleaved cytoplasmic L1 fragments into the
extracellular space. The cleavage occurs in both the endo-
somal compartment and released exosomes [56].
Cancer-derived Exosomes Promote Metastasis
Cancer-derived exosomes have been shown to facilitate the
formation of premetastatic niche, the early changes in the
local microenvironment of a distant organ in preparation for
metastatic cancer cell embedding and growth. In a rat pan-
creatic adenocarcinoma model, cancer-derived exosomes
were shown to function together with a soluble matrix to
generate the premetastatic niche for pancreatic cancer me-
tastasis [57]. Neither exosome nor the soluble matrix alone
is sufficient for this premetastatic niche formation.
Exosomes Released by Cancer Stroma Cells
It is known that the cargo carried by exosomes is determined
by the donor cells. Conceivably, stroma cells also release
exosomes either constitutively or under induction by envi-
ronmental stimulation that can impact cancer cells and/or
other stromal cells [58]. The stromal cells in cancer include
ECs, fibroblasts, leukocytes (macrophages, dentritic cells,
T- and B-cells etc.), pericytes and smooth muscle cells, as
well as mesenchymal stem cells (MSCs) and other blood
precursor cells from the blood circulation.
ECs are known to release exosomes as well. The trans-
membrane notch ligand Dll4 has been demonstrated to be
incorporated not only into cancer cell exosomes but also
into endothelial exosomes [49]. These exosomes can trans-
fer Dll4 protein to other endothelial cells and cancer cells,
incorporate it into the recipient cell membrane, which results
in inhibition of Notch signaling. This observation suggests
that endothelial exosomes can transfer signal molecules to
other ECs as well as cancer cells in the cancer micro-
environment to influence cancer behavior.
It is well known that solid cancers are infiltrated by
immune cells of both innate immunity and adaptive immu-
nity [59–61]. Exosome production by various types of im-
mune cells has been well established [11, 62]. It is conceivable
that exosomes produced by cancer infiltrated immune cells
could mediate cell-cell communication between immune cells
and cancer cells as well as other stromal cells to modulate
cancer form and function.
Up to now, there has been no report of exosome release
by pericytes and smooth muscle cells. These are cells asso-
ciated with blood vessels in cancer. Therefore, the contribu-
tion of these two cell types to cancer microenvironment
through exosomes is unknown at the moment.
Exosomes from the Circulation and their Influence
on Cancer Microenvironment
Exosomes have been found in various biological fluids such
as blood, urine, sperm, milk and others [11]. Exosomes from
platelets have been shown to induce lung cancer metastasis
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and angiogenesis as well as promote breast cancer metasta-
sis [63, 64]. Exosome release by bone marrow derived
mesenchymal stem cells (MSCs) and other precursor cells
of the blood lineages, e.g. endothelial precursor cells (EPCs)
have been reported. MVs derived from EPCs are able to
promote EC survival, proliferation and capillary morpho-
genesis in vitro and stimulate angiogenesis in vivo. These
proangiogenic effects were shown to be mediated by mRNA
transfer from EPCs to ECs involving the PI3K/AKT signal-
ing pathway [65]. Judging from the isolation method used,
the MVs in this study are most likely exosomes. In addition,
cancer is known to be in a prothrombotic state, with an
increased prevalence of venous thromboembolism. Plasma
tissue factor positive microparticles (MPs) have been pos-
tulated to contribute to venous thromboembolism since its
level is significantly higher in cancer patients with throm-
boembolism [66]. Whether circulating exosomes also con-
tribute to the prothrombotic state of cancer is unclear at the
moment. Furthermore, as all the data on exosomes obtained
so far are based on exosomes purified and concentrated in
vitro, it is therefore unclear whether physiological levels of
circulating exosomes perform similar functions.
Exosomes as a Cancer Defense Mechanism
Exosomes are able to influence both the innate immune
response and the adaptive immune system. Although exo-
somes have been shown to suppress inflammation [67, 68],
most work on cancer exosomes have focused on their ability
to manipulate lymphocytes. Cancer exosomes are able to
influence the proliferation of cytotoxic effector cells and
regulatory T (Treg) cells. In addition, they are also able to
influence the activation of naïve T-cells. We will present a
brief summary here. For more elaborate coverage in this
area, refer to other recent reviews in this area [11, 69–71].
Cancer exosomes are involved in cancer immune evasion
by suppressing the host immune system. Immune suppres-
sion can be accomplished by several means; mechanisms
involved in eliciting an immune response could be hindered;
or those involved in immune suppression bolstered. Cancer
exosomes have been shown to be able to impair the function
of Natural Killer (NK) and Cytotoxic CD8+ T-cells by
reducing the expression of the receptor NKG2D, which is
required for their activation, via exosomal TGFβ1 [72]. In
addition, cancer exosomes impaired CD4+ T cell mediated
NK and CD8+ T cell proliferation in response to IL-2 [73].
Cancer exosomes also induce apoptosis in CD8+ T-cells
whilst inducing the proliferation and generation of the im-
munosuppressive Treg cells [74]. Cancer exosomes have
also been shown to mediate the conversion of CD4+ T cells
into Treg cells, promote Treg suppressor function and in-
crease their resistance to apoptosis [75]. Another function of
cancer exosomes is to influence the functions of myeloid-
derived suppressor cells (MDSCs) which are known to
negatively regulate immune responses during cancer and
other diseases [76]. Cancer exosomes induce the accumula-
tion of these immune-suppressing MDSCs. Upon exosome
uptake, MDSCs increase the production of inflammatory
cytokines and promote tumor growth [77]. Hence cancer
exosomes are able to interfere with the immune system
and aid in cancer immune evasion.
On the other hand, cancer exosomes carry a subset of
antigens from their host cells. Hence it is possible that
antigen presenting cells (APCs) are able to process exo-
somes and present the tumor antigens to CD4+ T cells,
eventually triggering an anti-tumor immune response. It
has been demonstrated that dendritic cells (DCs), when
pulsed with cancer exosomes, promote the activation of
CD8+ T-cell-dependant anti-tumor response [20]. In con-
trast, cancer exosomes inhibited DC maturation and con-
ferred immunosuppression specific to antigens that are
present on the exosomes [78]. Furthermore, exosomes that
bear tumor antigens are shown to sequester tumor reactive
antibodies, thus reducing the susceptibility of tumor to an-
tibody dependant cellular cytotoxicity [79].
It seems that cancer exosomes can work both for and
against tumor survival by influencing different cells in the
immune system. Further studies are needed to elucidate the
physiological relevance and the extent that cancer exosomes
contribute to the various immune responses to clarify the
significance of exosomes in cancer immune evasion.
Exosomes as Diagnostic and Prognostic Markers
for Cancer
The importance of finding diagnostic markers for cancer
patients is not a new topic. Over the past few years, many
approaches have been reported for replacing the invasive
approach of diagnosing cancer by tissue biopsies with much
simpler and non-invasive approaches. The existence of cir-
culatory proteins and nucleic acids in bodily fluids of cancer
patients in form of exosomes has presented an opportunity
to develop novel diagnostic markers through non-invasive
means. One advantage of using exosomes as biomarkers are
the enrichment of markers within exosomes which would
otherwise constitute only a small fraction of the total secret-
ed proteins. The presence of highly enriched protein in body
fluids normally diminish the minor presence of relevant
biomarkers that could provide vital information into disease
or pathology [80].
It has been shown that the number of exosomes in body
fluids is elevated in cancer patients. The presence of tumor-
derived exosomes was initially reported as small membrane
fragments of endocytic origin in the peripheral circulation of
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women with ovarian cancer [81]. Subsequent study by the
same group using exosomes purified through immunoaffin-
ity purification against epithelial cell adhesion molecule
EpCAM showed that ovarian cancer derived exosomes in-
crease with progressive stages of ovarian cancer develop-
ment [82]. In this study, the identity of the purified
exosomes was validated by electron microscopy and West-
ern blot with exosome markers. In patients with lung ade-
nocarcinoma, circulating exosomes were significantly
higher than in control group [83]. Furthermore, in glioblas-
toma, the tumour-specific EGFRvIII splice variant was
detected in serum exosomes from some glioblastoma
patients by nested RT-PCR but not from exosomes derived
from normal control serum, indicating the potential of exo-
somes as cancer diagnostic markers [34].
Proteomic studies on urinary exosomes have generated a
long list of molecular markers that offers a potential for
diagnostic and prognostic discovery. Exosomes derived
from cultured bladder cancer cells contain more than 350
proteins, some of them were found in urinary exosomes of a
bladder cancer patient [84]. Moreover, analysis of urinary
exosomes from prostate cancer patients has revealed two
known tumor biomarkers, PCA-3 and TMPRSS2:ERG, in-
dicating the potential of using exosomes for prostate cancer
diagnostics [85].
More extensive identifications of cancer biomarkers are
required in order to offer more reliable diagnosis for cancer.
However, despite all the work and effort that has been done
so far, this area of research remains to be challenging. The
small size of exosomes is still a barrier in identifying the
mechanism of their interactions with other cells and delivery
in a dynamic fashion. The low level of exosomes from
biological fluid is also a major limitation for exosome pro-
teins to be reliable cancer markers in all patients. The
discovery of mRNA and miRNA in exosomes offer the
opportunity to develop the sensitive PCR-based diagnostic
and prognostic methods for cancer clinical applications.
Conclusion and Future Perspectives
Increasing number of studies has indicated that exosomes
play important roles in shaping the form and function of a
cancer. By serving as intercellular messengers, exosomes
transmit signaling pathways and even genetic materials not
only between cancer cells and stromal cells within the
primary cancer microenvironment, but also between cancer
and distant host organs. The main functions of exosomes in
cancer microenvironment are: (1) promote primary cancer
growth; (2) stimulate angiogenesis; (3) activate stromal
fibroblasts; (4) sculpture cancer ECM; (5) generate preme-
tastatic niche; (6) suppress host immune responses (Fig. 2).
The linkage of cancer-derived exosomes in blood circulation
specifically with the presence and extent of cancer develop-
ment is very promising for developing exosomes into reli-
able clinical diagnostic and prognostic markers for cancers.
Fig. 2 A schematic diagram showing the various functions of exosomes in cancer microenvironment
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Further development and standardization of the technolo-
gies and methods for exosomes isolation, analysis, specific
inhibition, removal from blood circulation as well as in
depth understanding of the molecular regulations of exo-
somes biogenesis and signal transduction are essential for
exosomes to serve as important tools in advancing cancer
biology and medicine.
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